Rising demand for access to affordable dialysis technology and reliable renal care equipment in India is increasing interest in domestically manufactured hemodialysis systems that has the potential to improve access and reduce reliance on imports. Against this backdrop, India’s hemodialysis market is projected to expand at a compound annual growth rate (CAGR) of 2.3% through 2036, forecasts GlobalData, a leading data and analytics company. 

GlobalData’s report, “Dialysis Machines Market Size by Segments, Share, Regulatory, Reimbursement, Installed Base and Forecast to 2036,” reveals that India’s hemodialysis machines market accounted for 2.7% share in APAC market  in 2025. This share is projected to increase, supported by a rising chronic kidney disease (CKD) burden, demand for affordable dialysis, and policy momentum toward medical device self-reliance.

India-based Bharat Electronics Limited (BEL) has recently received Central Drugs Standard Control Organisation (CDSCO) approval to manufacture the Renalyx-designed RXT17 hemodialysis machine. The clearance enables BEL to manufacture and market the RXT17 for clinical use, adding one of the first locally made option to the hemodialysis equipment market and supporting wider access to dialysis technology. Alongside Indian regulatory approval, the BEL RxT17 has obtained CE certification, confirming compliance with European safety, health, and environmental standards.

Priyanka Chakraborty, Medical Devices Analyst at GlobalData, comments: “While hemodialysis is essential for end-stage renal disease, access remains uneven due to high costs and dependence on imported systems. Approval of an indigenous platforms such as the RXT17 could expand supplier capacity, reduce import-related supply risks, and strengthen after-sales support for hospitals and dialysis centers.”

The BEL RxT17 is compatible with commonly used hospital pharmacy consumables and dialysis disposables, enabling easier adoption, smoother workflow integration, and lower transition costs. Its simplified design also supports easier operation and maintenance. 

Chakraborty concludes: “BEL’s entry reflects a growing involvement of public-sector and strategic enterprises in high-need medtech segments to strengthen healthcare resilience, helping build a more robust, patient-focused renal care ecosystem in India, for people requiring long-term CKD treatment.”